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RESEARCH ARTICLE
Radiation Dosimetry of a Novel Adenosine A2A
Receptor Radioligand [11C]Preladenant Based
on PET/CT Imaging and Ex Vivo Biodistribution
in Rats
Xiaoyun Zhou, Philip H. Elsinga, Shivashankar Khanapur, Rudi A. J. O. Dierckx,
Erik F. J. de Vries, Johan R. de Jong
Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen,
The Netherlands
Abstract
Purpose: [11C]Preladenant was developed as a novel adenosine A2A receptor PET radioligand.
The aim of this study was to determine the radiation dosimetry of [11C]preladenant and to investigate
whether dosimetry estimation based on organ harvesting can be replaced by positron emission
tomography (PET)/x-ray computed tomography (CT) imaging in rats.
Procedures: Male Wistar rats (n = 35) were i.v. injected with [11C]preladenant. The tracer
biodistribution was determined by organ harvesting at 1, 5, 15, 30, 60, and 90 min post injection.
Hollow organs including the stomach, intestines, and urinary bladder were harvested with contents. In
10 rats, a 90-min dynamic PET/CT scan of the torso was acquired. Twenty volumes of interest (VOIs)
were manually drawn on the PET image using the CT image of the same animal as anatomical
reference. The dynamic time-activity curves were used to calculate organ residence times (RTs).
Human radiation dosimetry estimates, derived from rat data, were calculated with OLINDA/EXM 1.1.
Results: PET-imaging and organ-harvesting estimated comparable organ RTs, with differences
of 6–27 %, except for the lungs, pancreas, and urinary bladder, with differences of 48, 53, and
60, respectively. The critical organ was the small intestine with a dose of 25 μSv/MBq. The
effective doses (EDs) calculated from imaging-based and organ-harvesting-derived data were
5.5 and 5.6 μSv/MBq, respectively, using the International Commission on Radiological
Protection 60 tissue weighting factors.
Conclusions: The ED of [11C]preladenant (2 mSv for a 370-MBq injected dose) is comparable with
other C-11-labeled PET tracers. Estimation of the radiation dosimetry of [11C]preladenant by PET/CT
imaging in rats is feasible and gives comparable results to organ harvesting, provided that small VOIs
are used and the content of hollow organs is taken into account. Dosimetry by PET imaging can
strongly reduce the number of laboratory animals required.
Key words: Radiation dosimetry, [11C]preladenant, Small-animal PET/CT, Adenosine A2A
receptor, Rat
Introduction
The adenosine A2A receptor (A2AR) has been studied as a
potential therapeutic target in peripheral inflammatory
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diseases [1] and in brain disorders, such as depression [2],
drug addiction [3], Alzheimer’s disease [4], and Parkinson’s
disease [5]. We have recently synthesized [11C]preladenant,
a novel positron emission tomography (PET) radioligand for
the imaging of A2AR in the central nervous system [6]. The
tracer displayed excellent target-to-non-target ratios as well
as favourable pharmacokinetic profiles, which warrants its
translation to studies in human subjects.
Before performing a clinical study, a radiation dosimetry
estimation is necessary to determine the dose limit of a new
radiopharmaceutical [7]. Experimental animals have been
used to estimate the radiation burden of a new tracer in
humans. Preclinical radiation dosimetry measurements are
often performed in non-human primates with PET imaging,
and in rodents with organ harvesting at several time points
post injection [8–10]. Due to the influence of the animal
rights movement, studies on non-human primates are subject
of discussion, while conventional ex vivo organ dissection in
rodents requires a large number of animals (i.e., 24 animals
for a typical ex vivo biodistribution study) to obtain the
dynamic biodistribution data of radiopharmaceuticals re-
quired for dosimetry calculations. With the improvement of
spatial resolution of the PET camera, small-animal PET
imaging emerges as a promising alternative to study tracer
distribution in vivo [11–14]. Dynamic PET-imaging enables
studying tracer biodistribution over time using a single
animal with much higher time resolution compared with
organ-harvesting. The first dosimetry study with PET
imaging in rodents was reported by Palm et al. [15], using
Y-86 Trastuzumab to estimate the absorbed doses of
[90Y]Trastuzumab in tumor and several organs in tumor-
bearing nude mice. Absorbed doses in mice were calculated
following the Medical Internal Radiation Dose (MIRD)
method, using the murine-specific S factors. However,
dynamic PET imaging data from previous studies showed
significant deviation from organ harvesting in multiple
organs, probably due to the small organ sizes comparative
to the low spatial resolution of the PET camera, resulting in
a severe partial volume effect (PVE)/spillover effect on
imaging data. Moreover, due to loss of contents of hollow
organs during the organ dissection, large discrepancies were
found in the measurements of hollow organ activities
between the two methods, as PET-imaging gives a measure
of organ walls and contents while the organ-harvesting
usually ignores the contribution of the organ contents.
In the present study, we determined the maximum
injected dose of [11C]preladenant for humans based on
whole-body PET imaging and ex vivo biodistribution in rats.
In order to minimize the PVE/spillover effects, high-
resolution small-animal x-ray computed tomography (CT)
was applied to aid with organ delineation. Furthermore,
spherical volumes of interest (VOIs) were drawn at the
center of the organs to further reduce PVE/spillover effect.
Finally, all hollow organs were dissected with contents;
therefore, the negative bias on activity estimates in hollow
organs due to loss of contents was avoided.
Materials and Methods
Radiochemistry
[11C]Preladenant was synthesized as described by Zhou et al. [6].
The radiochemical purity of [11C]preladenant was always greater
than 98 %. The specific activity of the product was 122 ± 28 GBq/
μmol (n = 11). [11C]Preladenant was formulated in phosphate
buffered saline (pH = 7.4) to give the final product ready for
injection.
Animals
Adult male Wistar rats (Hsd/Cpb:WU, Harlan, the Netherlands,
291 ± 18 g, n = 35) were housed in groups at a 12 h light/12 h dark
circle. The animals were fed with standard laboratory chow (RMH-
B, The Netherlands) and water ad libitum. After arrival, the rats
were allowed to acclimatized for at least 7 days. The research
protocols were approved by the Institutional Animal Care and Use
Committee of the University of Groningen (DEC 6689H).
Ex vivo Biodistribution
[11C]Preladenant (18 ± 10 MBq (0.15 ± 0.09 nmol) for organ-
harvesting only, 54 ± 20 MBq (0.48 ± 0.12 nmol) for organ
harvesting combined with 90 min PET-imaging) was i.v. adminis-
tered to rats (n = 5 per time point for time points 1–60 min, n = 10
for time point 90 min) via tail vein under isoflurane anesthesia
(isoflurane in oxygen at a flow rate of 0.8 l/min, 5 % isoflurane for
induction, 1.5–2.5 % isoflurane for maintenance). At 1, 5, 15, 30,
60, and 90 min post injection, animals were sacrificed by
extirpation of the heart. Major tissues (brain, heart, lungs, liver,
stomach, spleen, pancreas, kidney, small intestine, large intestine,
testes, and bladder) were harvested and weighted, and the activity
was measured using a calibrated well counter (2480 Wizard2,
PerkinElmer, Waltham, MA, USA). The hollow organs (i.e., heart,
intestines, stomach, and urinary bladder) were dissected with
contents. Activity in the stomach and intestines was corrected for
geometry effects due to the large volumes of these organs (with
contents), using the correction factors presented in Supplementary
Fig. 1. The data was expressed as Becquerel per gram tissue (Bq/g)
and then normalized to body weight and injected dose to obtain
standardized uptake values (SUVs) or converted to percent inject
dose per tissue (%ID). The data were corrected for radioactive
decay to the time of injection.
PET/CT Acquisition
During the PET/CT scan, animals were anesthetized with isoflurane
in oxygen at a flow rate of 0.8 l/min (5 % isoflurane for induction,
1.5–2.5 % isoflurane for maintenance) and kept on electronic
heating pads to avoid hypothermia. Small-animal PET/CT imaging
was performed with a dedicated small animal PET/CT scanner
(Inveon®, Siemens Preclinical Solutions, Knoxville, TN). Two bed
positions were acquired for CT and single bed position for PET to
have an axial field of view (FOV, ∼10 cm) covering all major
organs. The brain and neck were outside the FOV. A 18-min CT
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scan was carried out prior to the PET scan. Following the CT scan,
a 90-min dynamic PET acquisition was started at the time of i.v.
injection of [11C]preladenant (54 ± 20 MBq, n = 10). The emission
sinograms were corrected for attenuation, scatter, and decay. The
acquisition data was divided in 24 frames (6 × 10, 4 × 30, 2 × 60,
1 × 120, 1 × 180, 4 × 300, and 6 × 600 s). The data were recon-
structed per time frame using an ordered set expectation
maximization-3D/maximum a posteriori (OSEM3D/MAP) algo-
rithm, with a voxel size of 0.39 × 0.39 × 0.80 mm3 and matrix of
256.
Immediately after the PET scan, animals were terminated by
extirpation of the heart. Organs were harvested and measured with
a well counter.
Volumes of Interest
In order to minimize the resolution-related PVE and spillover
effects, spherical VOIs with diameters of 2.9–5.7 mm were
placed at the center of the heart, lungs, liver, stomach content,
spleen, pancreas, kidney contents, and testes on the PET/CT
fusion images by a single observer, using Inveon Research
Workplace (Siemens Medical Solutions, Knoxville, TN). For
paired tissues such as the lungs, kidney contents, and testes,
two VOIs were placed: one on the right and one on the left
side. For the liver, VOIs were placed in two separate lobes. For
the stomach wall, kidney wall, and intestines, VOIs were drawn
well inside the boundary of the organs. The small intestine
showed different tracer concentration at duodenum (first 8 %
section of small intestine) and the rest of small intestine.
Therefore, the two sections were delineated separately. Then,
the total activity in the small intestine was calculated as total
activity = 8 %*activity in duodenum + 92 %*activity in rest of
small intestine. The urinary bladder was delineated based on
the PET image. Examples of PET/CT co-registered images with
manually defined VOIs are shown in Fig. 1 and Supplementary
Fig. 2. The time-activity curves (TACs) were extracted from all
VOIs, expressed as Becquerel per volume (Bq/ml) vs. time.
Then, the Becquerel per volume was converted to Becquerel
per mass (Bq/g), assuming organ density to be 1 g/ml for all
organs except for lungs with a density of 0.33 g/ml [16].
Organ Activity
The activity in the heart, lungs, liver, spleen, pancreas, and
testes was calculated as activity concentration (Bq/g) multiplied
by the mass of the organs (Table 1). The activity in kidney and
stomach was the activity in organ walls plus the activity in
organ contents. The masses of organ and organ contents were
derived from a 300 g standard rat, based on the ex vivo
biodistribution data of a group of 22 rats from a previous study
(Hsd/Cpb:WU, Harlan, the Netherlands, 310 ± 20 g), by scaling
their organ weights and the ratios of organ weight to body
weight to that of an animal of 300 g (Table 1). The activity in
intestines was obtained from the activity concentration (Bq/
g)*mass of organ walls and contents, as the walls were
indistinguishable from the contents. The activity in urinary
bladder was computed as activity concentration (Bq/g)*mass of
urinary bladder, where the mass was derived from the PET
image (mass (g) = volume of bladder VOI (ml)*1 g/ml), with an
average value of 0.29 g (Supplementary Fig. 2).
Global Correction Factor (GCF)
The GCFs were generated to correct for PET imaging-derived
activity in the lungs, urinary bladder and pancreas for spillover
effects. The GCF was calculated by dividing the harvesting-
based activity at 90 min post injection by the mean activity of
the last frame (80–90 min) of PET imaging of the same animal.
The PET imaging-derived TACs were corrected by multiplica-
tion with the GCF for all time points.
Residence Time Calculation
The decay-corrected TACs were converted into TACs without
decay correction, using the following formula: A = A0*2^[(t0-t)/
T1/2], where A0 is the decay-corrected activity at time t, t0 is the
time of injection. T1/2 is the half-life of
11C (= 0.34 h). The
residence time (RT) in each organ was computed by integration
of the area under the TAC (%ID vs. time). Area under the curve
(AUC) between the start and the end of scan was calculated
using trapezoidal numerical integration of AUC. The integral
between the end of scan to the infinity was calculated as
Aend*0.49 h, where Aend is the activity at the end of scan,
normalized to 1 MBq injected. The activity in tissues other than
listed in Table 1 was grouped together as remainder. The
remainder of the body was assumed to have a homogenous
distribution of activity. The RT for the remainder was calculated
by subtracting the RTs of all source organs from the theoretical
total body RT of 0.49 h (= 0.34 h/ln2), assuming no excretion of
activity.
The RTs for humans (RTh) were extrapolated from rat RTs
(RTr) based on the difference of tissue-to-body mass ratio (Eq. 1),
where Oh = human organ weight, Or = rat organ weight, Bh = human
body weight, Br = rat body weight [17].






The dose calculations were in accordance with MIRD pamphlet No.
21 [18]. OLINDA/EXM 1.1 software [19] was applied to estimate
organ-absorbed doses and the effective dose (ED) of a 70-kg
reference adult phantom [20]. The doses were obtained without
GCF correction. Equation 2 shows the absorbed dose (μSv/MBq)
calculation of target organ i. The RT(j) is the RT in organ j (source
organ), S (j,i) is the phantom-specific dose factor (S value) between
the source organ j and target organ i. The EDs were computed
based on tissue weighting factors from International Commission
on Radiological Protection (ICRP) 60 [21] and ICRP 103 [22]. Ex
vivo biodistribution data were calculated for average doses as well
as maximum/minimum doses to assess worst/best case scenarios.
The RTs used for obtaining maximum and minimum doses were
computed from AUCs, where the maximum AUC was cumulative
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activity + 95 % confidence interval, and the minimum value was
cumulative activity - 95 % confidence interval.
Dose ið Þ ¼
X
j
RT jð Þ  S j; ið Þ ð2Þ
Results
Accumulation of [11C]preladenant in the stomach wall, liver,
kidney, small intestine, and urinary bladder was clearly
visual on the PET images (Figs. 1 and 2 and Supplementary
Fig. 2). The highest tracer concentration was found in the
duodenum and stomach wall, showing maximum SUVs of
28.4 ± 7.9 and 18.9 ± 3.1 (imaging data), respectively, at
90 min post injection. PET imaging and organ harvesting
gave comparable SUVs, as is shown in Fig. 3. Figure 4
illustrates the dynamic distribution of [11C]preladenant in
multiple rat organs derived from PET imaging and organ
harvesting. The activity was corrected for decay to the time
of injection. The highest total organ tracer uptake was found
in the liver, with a peak of 39.2 ± 4.3 % injected activity at
8.5 min post injection for PET-imaging data, and 28.6 ±
9.5 % injected activity at 5 min post injection for ex vivo
biodistribution data. The brain, kidneys, heart, lungs, spleen,
and pancreas displayed rapid tracer clearance, with a peak
uptake within 1 min. The small intestine, large intestine,
stomach, and urinary bladder exhibited continuously in-
creasing uptake for the total scan duration of 90 min.
The residence times and the percentage of injected dose
for the human adult model derived from rat organ activity
are listed in Table 2. The highest cumulative activity was
found in the liver and small intestine, with RTs of 9.43E-02
± 0.63E-02 h and 7.03E-02 ± 1.95E-02 h for imaging-based
data, and 7.26E-02 h and 7.64E-02 h for organ harvesting-
based liver and small intestine data, respectively. The data
indicated that the tracer was mainly excreted by the
hepatobiliary system, as this accounted for the excretion of
930 % of activity, whereas merely G1.2 % activity was
found in the urinary bladder (no voiding). The imaging-
based RTs were in agreement with organ harvesting-based
values in general, with a mean difference of 24 % (range 6–
27 %, except for the lungs, pancreas, and urinary bladder,
with differences of 48, 53, and 60 %, respectively). When
the GCFs were applied to imaging-derived TACs of the
lungs, pancreas, and urinary bladder, the resulting RT values
for the lungs and pancreas became comparable with organ-
Fig. 1 a Coronal, b saggital and c transversal view of a representative PET/CT scan with the manually defined volumes of
interest.
Table 1. Organ masses (mean ± SD) and organ-to-body mass ratios (O/B)
of a 300-g standard male Wistar rat
Organ Mass (g) O/B (%)
Brain 1.95 ± 0.08 0.63
Heart 0.92 ± 0.09 0.31
Lung 1.25 ± 0.11 0.42
Liver 12.88 ± 0.92 4.29
Spleen 0.55 ± 0.05 0.18
Pancreas 0.98 ± 0.11 0.33
Kidneys 2.35 ± 0.13 0.76
Urinary bladder 0.07 ± 0.02 0.02
Testes 2.92 ± 0.19 0.97
Small intestine wall 1.95 ± 0.11 0.65
Colon wall 0.67 ± 0.23 0.22
Caecum wall 0.33 ± 0.06 0.11
Stomach wall 1.20 ± 0.21 0.40
Small intestine content 5.23 ± 2.00 1.74
Colon content 2.70 ± 1.20 0.90
Caecum content 3.17 ± 0.65 1.06
Stomach content 2.45 ± 1.36 0.82
*Kidney content 0.37 ± 0.03 0.12
*The mass was calculated (1 g = 1 ml) from the volume (0.374 ml)
delineated on the PET/CT image (n = 3)
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harvesting-derived RTs, with differences below 17 %.
However, this method was not valid for urinary bladder, as
the difference between methods increased to 80 % after
correction (Supplementary table 1).
The highest organ dose was received by the small
intestine (imaging: 23.2 μSv/MBq, harvesting: 25.1 μSv/
MBq), and followed by the liver (imaging: 16.8 μSv/MBq,
harvesting: 15.1 μSv/MBq), stomach wall (imaging:
8.9 μSv/MBq, harvesting: 12.5 μSv/MBq), and the kidneys
(imaging: 8.4 μSv/MBq, harvesting: 7.2 μSv/MBq) (Ta-
ble 3). ED estimates were similar between PET-imaging and
organ-harvesting methods, being 5.1 ± 0.3 μSv/MBq for
Fig. 2 Representative coronal PET images of the distribution of [11C]preladenant in the rat body at different times post
injection (PI).
Fig. 3 a Correlation between the tracer uptake in multiple organs (SUVs) derived from the last frame (80–90 min post injection)
of PET-imaging and the tracer uptake obtained from organ harvesting of the same animals at 90 min post injection. b Bland-
Altman analysis on the same set of data. The solid line shows an average bias of +27 %, the dashed lines represent the 95 %
confidence intervals. Avg SUV = (SUVImaging + SUVHarvesting)/2, Δ = 2 × 100 × (SUVImaging − SUVHarvesting)/(SUVImaging +
SUVHarvesting). (n = 10, data from the heart, liver, spleen, pancreas, kidney, testes, intestines, and stomach were used for
comparison).
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PET-imaging, and 5.1 μSv/MBq for organ-harvesting, with
a range between 4.4 and 5.8 μSv/MBq (ICRP 103). When
the weighting factors from ICRP 60 were used in the
calculation, the resulting EDs were 5.5 ± 0.4 μSv/MBq for
PET-imaging, and 5.6 μSv/MBq for organ-harvesting. When
the source organs listed in Table 2 were reduced to organs
with uptake visually higher than the background on the PET
image (stomach, liver, kidney, small intestine, urinary
bladder, lungs (lungs were not visible on the PET image,
however the activity concentration in lungs was 3.3 times
higher than presented on the image. Therefore, lung was also
included as a source organ); Figs. 1 and 2), the EDs based
on RT values of lungs and visible source organs only were
4.7 ± 0.2 μSv/MBq for PET-imaging, and 4.6 μSv/MBq for
organ-harvesting, based on ICRP 103, and was 5.1 μSv/
MBq for both PET-imaging and organ-harvesting, based on
ICRP 60.
Discussion
Preclinical radiation dosimetry is a common approach to
estimate the activity that would be absorbed by humans in a
clinical study. Our study has shown that the ED of
[11C]preladenant (5.5 μSv/MBq, ICRP 60) projected from
the rat biodistribution data is within the same range as other
C-11 labeled PET tracers (3.0–16.0 μSv/MBq, mean
5.1 μSv/MBq) [23]. The dose limiting organ for
[11C]preladenant administration is the small intestine. A
PET study with [11C]preladenant can be performed in
human subjects using a maximum injection dose of
Fig. 4 Decay-corrected mean time-activity curves for [11C]preladenant in multiple rat organs obtained from PET imaging (a and
c) and organ harvesting (b and d).
Table 2. Human residence times (RTs, in Becquerel-hour per Becquerel injected) and percent inject dose (%ID) estimates for [11C]preladenant based on PET-
imaging and average organ-harvesting RTs from rats
RT_Imaging (mean ± SD) %ID_Imaging RT_Harvesting %ID_Harvesting
Testes 1.13 × 10−04 ± 0.30 × 10−04 0.02 1.49 × 10−04 0.03
Pancreas 2.09 × 10−03 ± 0.50 × 10−03 0.43 1.22 × 10−03 0.25
Spleen 2.25 × 10−03 ± 0.56 × 10−03 0.46 2.07 × 10−03 0.42
Heart 2.58 × 10−03 ± 0.45 × 10−03 0.53 2.43 × 10−03 0.49
Urinary bladder 3.15 × 10−03 ± 1.78 × 10−03 0.64 5.88 × 10−03 1.20
Lower large intestine wall 3.43 × 10−03 ± 0.99 × 10−03 0.70 4.31 × 10−03 0.88
Upper large intestine wall 4.52 × 10−03 ± 1.30 × 10−03 0.92 5.67 × 10−03 1.16
Kidneys 7.15 × 10−03 ± 0.89 × 10−03 1.28 5.94 × 10−03 1.21
Stomach 1.18 × 10−02 ± 0.19 × 10−02 2.40 1.41 × 10−02 2.87
Lungs 1.76 × 10−02 ± 0.28 × 10−02 3.58 1.07 × 10−02 2.19
Small intestine 7.03 × 10−02 ± 1.95 × 10−02 14.34 7.64 × 10−02 15.58
Liver 9.43 × 10−02 ± 0.63 × 10−02 19.23 7.26 × 10−02 14.79
Brain NA NA 6.84 × 10−03 1.39
Remainder 2.72 × 10−01 ± 0.25 × 10−01 55.48 2.82 × 10−01 57.53
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2.0 GBq based on the dose limit (50 mGy) to the small
intestine (Radioactive Drug Research Committee criteria).
When the maximum ED of 10 mSv is taken into account
[24], the maximum administered dose will be 1.8 GBq.
The conventional organ-harvesting method for radiation
dosimetry estimates has disadvantages such as laborious
sampling procedure, limited information obtained from
single animals, and low time resolution of the dynamic data,
resulting in experimental measured organ doses that deviate
from the true values. Small-animal PET imaging could
overcome these problems and serve as an alternative to
organ harvesting to study in vivo tracer biodistribution,
provided PVE and spillover effects are minimal. Our study
used a high-resolution small-animal PET camera with a
spatial resolution of 1.35 mm at the center of the FOV.
Furthermore, PET imaging was performed on rats, which
have larger organ sizes than mice. Therefore, it is possible to
define VOIs containing a sufficient number of voxels well
inside the boundary of organs to ensure sufficient counting
statistics. In addition, high-resolution CT images were co-
registered with PET images of the same animal that could
serve as anatomical references for organ delineation (Fig. 1).
Taken together, these approaches could substantially reduce
PVE/spillover effects due to the limited spatial resolution of
the PET camera. Thus, the reliability of PET-imaging data
can be greatly improved. Indeed, when we compared the
PET-imaging-derived activity uptake with activity uptake
obtained from organ-harvesting, a high degree of concor-
dance was found between the two measures (Fig. 3a). A
good correlation was observed by a linear regression model,
with a slope equal to 1.0, and a correlation (r2) of 0.89 (n =
10).
Our PET-imaging results, albeit superior to other pub-
lished data in terms of high agreement with organ-harvesting
measurements [12–14], still showed a small deviation from
organ-harvesting data. As is shown in Fig. 3b, a positive bias
was observed for PET-imaging, especially in regions with
low uptake. We assume that the overestimation of activity in
several organs with low uptake, such as the spleen, pancreas,
lungs, and kidneys, is due to spillover effects, as these
organs are adjacent to regions with high uptake, like the
stomach wall, liver and duodenum. Therefore, one can easily
imagine that the pancreas would be the most affected organ,
since it has a small volume, and is situated between organs
with the highest activity. Activity in the lungs measured by
PET-imaging also deviated substantially from activity
uptake obtained from organ-harvesting. Spillover of activity
from the liver would be one explanation. This spillover
effect was further enhanced by the 0.33 g/ml conversion
factor that was used to calculate the activity concentration in
the lungs. Thus, the spillover effect was tripled during the
calculation. Organs with high uptake seem to be less
affected by PVE, as the PET-imaging and organ-harvesting
estimated comparable values. Interestingly, we found that
the activity in the liver was higher measured with PET-
imaging than organ-harvesting. It is unlikely that the activity
measurement with PET was affected by spillover effect, as
the VOIs in the liver were far away from surrounding tissues
Table 3. Human organ-absorbed doses (μSv/MBq) and effective doses (μSv/MBq)
Organ PET-imaging %COV Harvesting_AVG Harvesting_Max Harvesting_Min
Adrenals 3.4 2.6 3.1 3.1 3.2
Brain 1.5 9.1 1.9 2.0 1.7
Breasts 1.8 5.8 1.8 1.6 2.0
Gallbladder wall 4.9 3.2 4.6 4.8 4.2
Lower large intestine wall 6.1 13.6 7.0 7.9 6.1
Small intestine 23.2 24.4 25.1 31.2 18.1
Stomach wall 8.9 10.7 10.1 12.5 7.5
Upper large intestine wall 7.4 12.0 8.3 9.5 6.9
Heart wall 3.8 9.7 3.5 3.7 3.2
Kidneys 8.4 10.0 7.2 7.9 6.3
Liver 16.8 6.3 13.2 15.1 10.7
Lungs 5.7 11.7 3.9 4.2 3.5
Muscle 2.2 3.6 2.2 2.1 2.4
Ovaries 3.9 7.8 4.2 4.5 3.9
Pancreas 8.2 16.2 5.8 6.5 5.0
Red marrow 2.2 1.3 2.3 2.2 2.3
Osteogenic cells 2.8 6.2 2.9 2.6 3.3
Skin 1.6 6.1 1.6 1.5 1.8
Spleen 4.9 16.4 4.6 6.0 3.2
Testes 1.5 10.1 1.9 1.9 1.8
Thymus 2.0 6.3 2.0 1.8 2.3
Thyroid 1.8 8.3 1.9 1.6 2.2
Urinary bladder wall 4.4 27.2 6.3 7.6 4.9
Uterus 3.6 7.0 3.9 4.1 3.7
Total body 2.9 0.2 2.8 2.8 2.9
Effective dose (ICRP 60) 5.5 6.8 5.6 6.3 4.7
Effective dose (ICRP 103) 5.1 6.0 5.1 5.8 4.4
COV coefficient of variation, calculated as SD/mean, AVG average, Max maximum, Min minimum
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(Fig. 1). Here we consider that the activity in the liver is
more reliable with PET-imaging than organ-harvesting,
because the body fluid loss in the liver during the ex vivo
biodistribution process might lead to an underestimation of
activity with organ-harvesting. As discussed above, the
activity was most concentrated in the stomach wall and
duodenum; therefore, the hepatic portal vein (75 % of liver
blood supply) and intrahepatic fluid may contain high levels
of activity, maybe even higher than the activity in
hepatocytes. When the heart was extirpated, the blood,
which makes up 30 % of total volume in the liver, is drained
way. The intrahepatic activity may also be taken away along
with blood loss. Therefore, the activity measured with
ex vivo biodistribution could be underestimated.
Despite the overestimation of activity with PET-imaging
in several organs with low activity uptake, an average bias of
+27 % is quite acceptable, because organs with low activity
uptake do not contribute much to the radiation dose
estimation. The bias is much smaller in organs with high
activity uptake, which are more important source organs for
dose estimation (Fig. 3). Furthermore, the cumulative
activity (AUC) estimates by both methods were similar,
with the exceptions of the pancreas, lungs, and urinary
bladder, as is shown in Table 2. The results suggest that the
spillover effect is the major factor leading to an overestima-
tion of activity with PET-imaging. However, such deviations
with PET-imaging were small and have been greatly reduced
by the strategies discussed above, in particular by drawing
small VOIs with regular shapes well inside the boundary of
organs and by dissecting hollow organs with contents.
The activity in urinary bladder was substantially
underestimated by 47 % with PET-imaging (Table 2). The
organ mass of the urinary bladder (0.29 g on average) calculated
from the volume of this organ on the PET images was different
from either the mass of urinary wall (0.07 g) or the urinary wall
with urine (0.5–4.5 g) measured with organ-harvesting. The
volume of the urinary bladder cannot be properly estimated by
PET because of the low activity in urine. The activity might have
a higher concentration around the ureter, where the urine was
delivered from the kidneys, making the small area visible from
the background. However, a large portion of urinary bladder and
urine was not visible, resulting in an underestimation of activity
as only the visible portion was considered in the calculation.
However, since the activity was low in the urinary bladder, the
inaccurate measurement with PET-imaging would not signifi-
cantly impair the dose estimation, as the urinary bladder was
neither a source organ, nor a critical organ in this case.
In order to reduce PET resolution-associated PVE and
spillover effect, several methodologies have been applied to
improve data accuracy, such as region-based PVE correction
reported by Lehnert, et al. [25], and the use of GCFs based on
ex vivo biodistribution data, as was suggested by Kesner, et al.
[13]. The former technique is robust and resulted in good
recovery of activity in small VOIs. However, it requires accurate
anatomic information. Since not all structures are identifiable
with CT imaging, and the shapes of the organs can be different
between scans, it becomes very complicated or even impossible
to apply this methodology to the whole-body scan. A simpler
method is the GCF correction which was tested in our study.
The major limitation of this method is that it does not change the
shape of the TACs in organs after correction, whereas the PVE/
spillover effect has a dynamic impact on TACs, as it is affected
by the activity kinetics in adjacent tissues. The global correction
failed to correct the activity in urinary bladder, since the
mismatch of activity in this organ with PET-imaging was not
due to PVE. Since the uptake in pancreas and lungs was affected
by spillover from the liver, GCF correction substantially
improved the results in these organs. Other organs showed
comparable results between PET-imaging and organ-harvesting,
indicating that the PVE was small. Considering the disadvan-
tages of global correction, which may introduce a bias and
impair the PET-imaging results, and considering the reliability
of organ-harvesting data, especially in the liver, global
correction was not used in the dose calculations. Even without
global correction the ED and critical organ dose estimates were
similar between PET-imaging and organ-harvesting, indicating
that the PVE correction is not crucial in our dosimetry study.
Therefore, ex vivo biodistribution after PET scanning can be
omitted.
In our study, the head and neck regions were not scanned
because (1) the head and neck were not expected to show
relevantly high uptake (based on ex vivo biodistribution and our
previous studies); thus, tracer uptake in these regions had very
small contribution to the dose calculation. (2) Technical hurdles.
The PET/CTmodality requiresmanual positioning of animals on
bothPETandCTsideswhenwhole-bodyPETscan is performed,
resulting in difficulty in coregistration of PET and CT images.
Furthermore, PET scanningwith continuous bedmotion leads to
dynamic images with low time-resolution and low statistical
quality. In our particular case, the impact on dosimetry of
including the head and neck region was deemed too small to
justify its cumbersomeness and reduced image quality. In case of
the brain and neck as possibly critical organs, PET imaging of
these regions is necessary and is best possible with our PET/CT
system by scanning each animal twice with one scan on the
head + upper torso and the other on the lower part of the body.
Conclusions
The ED of [11C]preladenant is comparable with other C-11
labeled PET tracers. A single injection dose of 370 MBq
(10 mCi) should be easily allowed for the first PET study in
humans. Estimation of the radiation dosimetry of
[11C]preladenant by PET/CT imaging in rats is feasible and
gives comparable results as organ harvesting, provided that
small VOIs with regular shapes are used and the content of
hollow organs is taken into account. Dosimetry by PET-
imaging can thus strongly reduce the number of laboratory
animals required.
Acknowledgments. We thank Janine Doorduin, Jürgen Sijbesma, Rolf
Zijlma and Tim van der Goot for technical assistance.
296 X. Zhou et al.: Preclinical dosimetry for [11C]preladenant
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflicts of interest.
Open Access This article is distributed under the terms of the Creative
Commons Attribution 4.0 International License (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction
in any medium, provided you give appropriate credit to the original author(s)
and the source, provide a link to the Creative Commons license, and indicate if
changes were made.
References
1. Antonioli L, Blandizzi C, Pacher P, Haskó G (2013) Immunity,
inflammation and cancer: a leading role for adenosine. Nat Rev Cancer
13:842–857
2. Cunha RA, Ferré S, Vaugeois JM, Chen J (2009) Potential therapeutic
interest of adenosine A2A receptors in psychiatric disorders. Curr
Pharm Des 14:1512–1524
3. Ferré S, Diamond I, Goldberg SR et al (2007) Adenosine A2A receptors
in ventral striatum, hypothalamus and nociceptive circuitry. Implica-
tions for drug addiction, sleep and pain. Prog Neurobiol 83:332–347
4. Dall’Igna OP, Porciúncula LO, Souza DO et al (2003) Neuroprotection
by caffeine and adenosine A2A receptor blockade of beta-amyloid
neurotoxicity. Br J Pharmacol 138:1207–1209
5. Sherzai A, Dimitrova T, Favit A et al (2003) Adenosine A2A receptor
antagonist treatment of Parkinson’s disease. Neurology 61:293–296
6. Zhou X, Khanapur S, Huizing AP et al (2014) Synthesis and preclinical
evaluation of 2 (2-Furanyl)-7-[2-[4-[4- (2 [11C]methoxyethoxy)phenyl]-
1- piperazinyl]ethyl]7H pyrazolo[4,3 e][1,2,4]triazolo [1,5 c]pyrimi-
dine- 5-amine ([11C]Preladenant) as a PET tracer for the imaging of
cerebral adenosine A2A receptor. J Med Chem 57:9204–9210
7. Verbruggen A, Coenen HH, Deverre JR et al (2008) Guideline to
regulations for radiopharmaceuticals in early phase clinical trials in the
EU. Eur J Nucl Med Mol Imaging 35:2144–2151
8. Brown AK, Fujita M, Fujimura Y et al (2007) Radiation dosimetry and
biodistribution in monkey and man of 11C-PBR28: a PET radioligand to
image inflammation. J Nucl Med 48:2072–2079
9. Doss M, Kolb HC, Zhang J et al (2012) Biodistribution and radiation
dosimetry of the integrin marker 18F-RGD-K5 determined from whole-
body PET/CT in monkeys and humans. J Nucl Med 53:787–795
10. Ishiwata K, Wang W, Kimura Y et al (2003) Preclinical studies on
[11C]TMSX for mapping adenosine A2A receptors by positron emission
tomography. Ann Nucl Med 17:205–211
11. Luoto P, Laitinen I, Suilamo S et al (2010) Human dosimetry of carbon-11
labeled N-butan-2-yl-1-(2-chlorophenyl)-N-methylisoquinoline-3-carboxamide
extrapolated fromwhole-body distribution kinetics and radiometabolism in rats.
Mol Imaging Biol 12:435–442
12. Constantinescu CC, Sevrioukov E, Garcia A et al (2013) Evaluation of
[18F]Mefway biodistribution and dosimetry based on whole-body PET
imaging of mice. Mol Imaging Biol 15:222–229
13. Kesner AL, Hsueh WA, Czernin J et al (2008) Radiation dose estimates
for [18F]5-fluorouracil derived from PET-Based and tissue-based
methods in rats. Mol Imaging Biol 10:341–348
14. Bretin F, Warnock G, Bahri MA et al (2013) Preclinical radiation
dosimetry for the novel SV2A radiotracer [18F]UCB-H. EJNMMI Res
3:35
15. Palm S, Enmon RM, Matei C et al (2003) Pharmacokinetics and
biodistribution of (86)Y-trastuzumab for (90)Y dosimetry in an ovarian
carcinoma model: correlative MicroPET and MRI. J Nucl Med
44:1148–1155
16. Rhodes CG, Wollmer P, Fazio F, Jones T (1981) Quantitative
measuremnt of regional extravascular lung density using postiron
emission and transmission tomography. J Comput Assist Tomogr
5:783–791
17. Kirschner AS, Ice RD, Beierwaltes WH (1975) Radiation dosimetry of
131 I-19-Iodocholesterol: the pitfalls of using tissue concentration
data—reply. J Nucl Med 16:248–249
18. Bolch WE, Eckerman KF, Sgouros G, Thomas SR (2009) MIRD
pamphlet no. 21: a generalized schema for radiopharmaceutical
dosimetry—standardization of nomenclature. J Nucl Med 50:477–
484
19. Stabin MG, Sparks RB, Crowe E (2005) OLINDA/EXM: the second-
generation personal computer software for internal dose assessment in
nuclear medicine. J Nucl Med 46:1023–1027
20. Cristy M, Eckerman KF (1987) Specific absorbed fractions of energy at
various ages from internal photon sources. VII. Adult male. Oak Ridge
National Laboratory, Oak Ridge, pp V1–V7, ORNL/TM-8381
21. ICRP (1991) ICRP 60: 1990 Recommendations of the International
Commission on Radiological Protection. ICRP Publication 60. Ann
ICRP 21 (1–3):60
22. ICRP (2007) ICRP 103: the 2007 Recommendations of the International
Commission on Radiological Protection. ICRP Publication 103. Ann
ICRP (2–4)
23. Zanotti-Fregonara P, Innis RB (2012) Suggested pathway to assess
radiation safety of 11C-labeled PET tracers for first-in-human studies.
Eur J Nucl Med Mol Imaging 39:544–547
24. (1993) ICRP Publication 62: Radiological Protection in Biomedical
Research. Annals of the ICRP Volume 22/3: International Commission
on Radiological Protection
25. Lehnert W, Gregoire MC, Reilhac A, Meikle SR (2012) Characterisa-
tion of partial volume effect and region-based correction in small animal
positron emission tomography (PET) of the rat brain. Neuroimage
60:2144–2157
X. Zhou et al.: Preclinical dosimetry for [11C]preladenant 297
